Brought to you by 
Fujirebio buys Centocor's oncology Dx business for $37.5mm
13 Jul 1999
Executive Summary
Centocor (MAb-based drugs and tests) is selling its oncology diagnostics business to Fujirebio, a leading Japanese diagnostics company, for $37.5mm in cash (about 1 x sales).
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Chemistry, Immunoassay
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Fujirebio buys Centocor's oncology Dx business for $37.5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice